Skip to content

Event I May 24-25, 2023

5th International Meeting of Cell-Free DNA

We are excited to announce that we will be attending the cfDNA2023 conference. The meeting promises to provide an excellent overview of the field as presented by key experts and give us the opportunity to discuss scientific and clinical topics with peers from the field. We look forward to learning from and contributing to the conversation at cfDNA2023.

Get in touch


“During early pregnancy, 3-6% of cell-free DNA in the plasma of pregnant women is of fetal origin.”

Dr. Agneta Wikman, M.D., Ph.D, Karolinska University Hospital, Stockholm, Sweden

Take a look at our whitepaper

Dr. Agneta Wikman, Associate Professor at Karolinska University Hospital explores an approach that uses non-invasive prenatal testing to determine the fetal RHD status, allowing targeted administration of antenatal anti-D prophylaxis only to those who will benefit from it. Learn more about the current strategies of fetal RHD and the experiences and considerations surrounding planning a fetal RHD screening program.


Listen to the audio & e-book

Choosing and implementing the best screening method for non-invasive fetal-RHD testing. Learn from clinical experts about the shift in today’s screening method for non-invasive fetal-RHD testing. Dr Wikman is a professor and specialist in Transfusion Medicine and Laboratory Medicine.


Agneta & Annika-1